{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:18:25Z","timestamp":1780640305870,"version":"3.54.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Institute of Health","award":["AG039625"],"award-info":[{"award-number":["AG039625"]}]},{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"crossref","award":["B6285R"],"award-info":[{"award-number":["B6285R"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.vaccine.2011.08.009","type":"journal-article","created":{"date-parts":[[2011,8,19]],"date-time":"2011-08-19T05:17:05Z","timestamp":1313731025000},"page":"7631-7637","source":"Crossref","is-referenced-by-count":10,"title":["Wheat germ agglutinin enhanced cerebral uptake of anti-A\u03b2 antibody after intranasal administration in 5XFAD mice"],"prefix":"10.1016","volume":"29","author":[{"given":"Neelima B.","family":"Chauhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2011.08.009_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3233\/JAD-2010-100975","article-title":"Alzheimer's disease: a general introduction and pathomechanism","volume":"22","author":"Finder","year":"2010","journal-title":"J Alzheimers Dis"},{"issue":"July (1)","key":"10.1016\/j.vaccine.2011.08.009_bib0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00401-009-0532-1","article-title":"Classification and basic pathology of Alzheimer disease","volume":"118","author":"Duyckaerts","year":"2009","journal-title":"Acta Neuropathol"},{"issue":"June (2\u20133)","key":"10.1016\/j.vaccine.2011.08.009_bib0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12035-010-8109-5","article-title":"Convergence of amyloid-beta and tau pathologies on mitochondria in vivo","volume":"41","author":"Eckert","year":"2010","journal-title":"Mol Neurobiol"},{"issue":"1","key":"10.1016\/j.vaccine.2011.08.009_bib0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/JAD-2009-0960","article-title":"Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease","volume":"16","author":"Huang","year":"2009","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2011.08.009_bib0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2183\/pjab.86.54","article-title":"The biochemical study on the etiology of Alzheimer's disease","volume":"86","author":"Imahori","year":"2010","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"April (3)","key":"10.1016\/j.vaccine.2011.08.009_bib0030","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.arcmed.2010.03.007","article-title":"The revitalized tau hypothesis on Alzheimer's disease","volume":"41","author":"Maccioni","year":"2010","journal-title":"Arch Med Res"},{"issue":"November (4)","key":"10.1016\/j.vaccine.2011.08.009_bib0035","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.neuron.2008.11.007","article-title":"Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis","volume":"60","author":"Small","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.vaccine.2011.08.009_bib0040","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","article-title":"Active and passive immunotherapy for neurodegenerative disorders","volume":"31","author":"Brody","year":"2008","journal-title":"Annu Rev Neurosci"},{"issue":"December (6)","key":"10.1016\/j.vaccine.2011.08.009_bib0045","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1586\/14760584.3.6.717","article-title":"Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease","volume":"3","author":"Chauhan","year":"2004","journal-title":"Expert Rev Vaccines"},{"issue":"October (9647)","key":"10.1016\/j.vaccine.2011.08.009_bib0050","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0140-6736(08)61578-0","article-title":"Amyloid-beta vaccination for Alzheimer's dementia","volume":"372","author":"Holtzman","year":"2008","journal-title":"Lancet"},{"issue":"September (4)","key":"10.1016\/j.vaccine.2011.08.009_bib0055","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2174\/156720507781788800","article-title":"Novel Abeta immunogens: is shorter better?","volume":"4","author":"Lemere","year":"2007","journal-title":"Curr Alzheimer Res"},{"issue":"October (9647)","key":"10.1016\/j.vaccine.2011.08.009_bib0060","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0140-6736(08)61579-2","article-title":"Amyloid-beta vaccination for Alzheimer's dementia","volume":"372","author":"McGeer","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2011.08.009_bib0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000090365","article-title":"A beta immunotherapy: lessons learned for potential treatment of Alzheimer's disease","volume":"2","author":"Schenk","year":"2005","journal-title":"Neurodegener Dis"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2011.08.009_bib0070","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(08)70170-4","article-title":"Amyloid-beta immunisation for Alzheimer's disease","volume":"7","author":"Wisniewski","year":"2008","journal-title":"Lancet Neurol"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2011.08.009_bib0075","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2202-9-S3-S5","article-title":"Intranasal delivery bypasses the blood\u2013brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease","volume":"9","author":"Hanson","year":"2008","journal-title":"BMC Neurosci"},{"issue":"February (1\u20133)","key":"10.1016\/j.vaccine.2011.08.009_bib0080","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery \u2013 possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003","journal-title":"J Control Release"},{"issue":"June (4)","key":"10.1016\/j.vaccine.2011.08.009_bib0085","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/713714452","article-title":"Drug transport into the mammalian brain: the nasal pathway and its specific metabolic barrier","volume":"10","author":"Minn","year":"2002","journal-title":"J Drug Target"},{"issue":"June (3)","key":"10.1016\/j.vaccine.2011.08.009_bib0090","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1023\/B:PHAR.0000026823.82950.ff","article-title":"Nasal route and drug delivery systems","volume":"26","author":"Turker","year":"2004","journal-title":"Pharm World Sci"},{"issue":"2","key":"10.1016\/j.vaccine.2011.08.009_bib0095","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.neuroscience.2004.05.029","article-title":"Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration","volume":"127","author":"Thorne","year":"2004","journal-title":"Neuroscience"},{"issue":"12","key":"10.1016\/j.vaccine.2011.08.009_bib0100","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2165\/00003088-200140120-00003","article-title":"Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations","volume":"40","author":"Thorne","year":"2001","journal-title":"Clin Pharmacokinet"},{"issue":"March (1)","key":"10.1016\/j.vaccine.2011.08.009_bib0105","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11481-006-9039-x","article-title":"Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS","volume":"2","author":"Hanson","year":"2007","journal-title":"J Neuroimmune Pharmacol"},{"issue":"August (3)","key":"10.1016\/j.vaccine.2011.08.009_bib0110","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jconrel.2007.05.026","article-title":"Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration","volume":"121","author":"Gao","year":"2007","journal-title":"J Control Release"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2011.08.009_bib0115","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1128\/JVI.72.1.807-810.1998","article-title":"Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB\/c mice","volume":"72","author":"Bourgeois","year":"1998","journal-title":"J Virol"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2011.08.009_bib0120","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1128\/IAI.70.3.1069-1074.2002","article-title":"Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia","volume":"70","author":"Gigliotti","year":"2002","journal-title":"Infect Immun"},{"issue":"June (18)","key":"10.1016\/j.vaccine.2011.08.009_bib0125","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1016\/j.biomaterials.2006.01.038","article-title":"Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration","volume":"27","author":"Gao","year":"2006","journal-title":"Biomaterials"},{"issue":"September (1\u20132)","key":"10.1016\/j.vaccine.2011.08.009_bib0130","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0006-8993(95)00637-6","article-title":"Quantitative analysis of the olfactory pathway for drug delivery to the brain","volume":"692","author":"Thorne","year":"1995","journal-title":"Brain Res"},{"issue":"October (40)","key":"10.1016\/j.vaccine.2011.08.009_bib0135","doi-asserted-by":"crossref","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","article-title":"Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation","volume":"26","author":"Oakley","year":"2006","journal-title":"J Neurosci"},{"issue":"October (2)","key":"10.1016\/j.vaccine.2011.08.009_bib0140","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/jnr.1215","article-title":"Distribution of intraventricularly administered antiamyloid-beta peptide (Abeta) antibody in the mouse brain","volume":"66","author":"Chauhan","year":"2001","journal-title":"J Neurosci Res"},{"issue":"June (3)","key":"10.1016\/j.vaccine.2011.08.009_bib0145","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2174\/156720508784533321","article-title":"Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses","volume":"5","author":"Cerpa","year":"2008","journal-title":"Curr Alzheimer Res"},{"issue":"October (5440)","key":"10.1016\/j.vaccine.2011.08.009_bib0150","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.286.5440.735","article-title":"Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE","volume":"286","author":"Vassar","year":"1999","journal-title":"Science"},{"issue":"July (16)","key":"10.1016\/j.vaccine.2011.08.009_bib0155","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1073\/pnas.161102498","article-title":"Presenilin-dependent gamma-secretase activity modulates thymocyte development","volume":"98","author":"Doerfler","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"November (6860)","key":"10.1016\/j.vaccine.2011.08.009_bib0160","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35102591","article-title":"A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity","volume":"414","author":"Weggen","year":"2001","journal-title":"Nature"},{"issue":"June (3)","key":"10.1016\/j.vaccine.2011.08.009_bib0165","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2174\/1568007033482869","article-title":"Role of acetylcholinesterase inhibitors in the metabolism of amyloid precursor protein","volume":"2","author":"Pakaski","year":"2003","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"issue":"March (1)","key":"10.1016\/j.vaccine.2011.08.009_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/13506120308995249","article-title":"Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease","volume":"10","author":"Hock","year":"2003","journal-title":"Amyloid"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2011.08.009_bib0175","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1073\/pnas.0230450100","article-title":"Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo","volume":"100","author":"Farris","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"January (4)","key":"10.1016\/j.vaccine.2011.08.009_bib0180","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1074\/jbc.C200642200","article-title":"Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme","volume":"278","author":"Eckman","year":"2003","journal-title":"J Biol Chem"},{"issue":"June (11)","key":"10.1016\/j.vaccine.2011.08.009_bib0185","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1523\/JNEUROSCI.20-11-03937.2000","article-title":"The plasmin system is induced by and degrades amyloid-beta aggregates","volume":"20","author":"Tucker","year":"2000","journal-title":"J Neurosci"},{"issue":"May (5521)","key":"10.1016\/j.vaccine.2011.08.009_bib0190","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1126\/science.1059946","article-title":"Metabolic regulation of brain Abeta by neprilysin","volume":"292","author":"Iwata","year":"2001","journal-title":"Science"},{"issue":"September (5177)","key":"10.1016\/j.vaccine.2011.08.009_bib0195","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1126\/science.8073293","article-title":"Rapid induction of Alzheimer A beta amyloid formation by zinc","volume":"265","author":"Bush","year":"1994","journal-title":"Science"},{"issue":"June (3)","key":"10.1016\/j.vaccine.2011.08.009_bib0200","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0896-6273(01)00317-8","article-title":"Treatment with a copper\u2013zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice","volume":"30","author":"Cherny","year":"2001","journal-title":"Neuron"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2011.08.009_bib0205","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/archneur.60.12.1685","article-title":"Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial","volume":"60","author":"Ritchie","year":"2003","journal-title":"Arch Neurol"},{"issue":"July (13)","key":"10.1016\/j.vaccine.2011.08.009_bib0210","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1007\/s00018-005-5599-9","article-title":"Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease","volume":"63","author":"Hamaguchi","year":"2006","journal-title":"Cell Mol Life Sci"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2011.08.009_bib0215","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nrn938","article-title":"Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning","volume":"3","author":"Schenk","year":"2002","journal-title":"Nat Rev Neurosci"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2011.08.009_bib0220","first-page":"867","article-title":"[Abeta vaccine therapy for Alzheimer's disease]","volume":"45","author":"Hara","year":"2005","journal-title":"Rinsho Shinkeigaku"},{"issue":"October (4)","key":"10.1016\/j.vaccine.2011.08.009_bib0225","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/1531-8249(200010)48:4<567::AID-ANA3>3.0.CO;2-W","article-title":"Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease","volume":"48","author":"Weiner","year":"2000","journal-title":"Ann Neurol"},{"issue":"December (6815)","key":"10.1016\/j.vaccine.2011.08.009_bib0230","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/35050110","article-title":"A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease","volume":"408","author":"Janus","year":"2000","journal-title":"Nature"},{"issue":"December (6815)","key":"10.1016\/j.vaccine.2011.08.009_bib0235","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","article-title":"A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease","volume":"408","author":"Morgan","year":"2000","journal-title":"Nature"},{"issue":"September\u2013October (5)","key":"10.1016\/j.vaccine.2011.08.009_bib0240","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0197-4580(01)00245-7","article-title":"Reduced effectiveness of Abeta1\u201342 immunization in APP transgenic mice with significant amyloid deposition","volume":"22","author":"Das","year":"2001","journal-title":"Neurobiol Aging"},{"issue":"August (2)","key":"10.1016\/j.vaccine.2011.08.009_bib0245","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0002-9440(10)61715-4","article-title":"Immunization with a nontoxic\/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice","volume":"159","author":"Sigurdsson","year":"2001","journal-title":"Am J Pathol"},{"issue":"October (21)","key":"10.1016\/j.vaccine.2011.08.009_bib0250","doi-asserted-by":"crossref","first-page":"11455","DOI":"10.1073\/pnas.97.21.11455","article-title":"Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration","volume":"97","author":"Frenkel","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2011.08.009_bib0255","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat Med"},{"issue":"July (15)","key":"10.1016\/j.vaccine.2011.08.009_bib0260","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","article-title":"Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease","volume":"98","author":"DeMattos","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"December (8)","key":"10.1016\/j.vaccine.2011.08.009_bib0265","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1517\/14712598.2.8.907","article-title":"Immunological approaches as therapy for Alzheimer's disease","volume":"2","author":"Solomon","year":"2002","journal-title":"Expert Opin Biol Ther"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2011.08.009_bib0270","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1089\/10445490152717550","article-title":"Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease","volume":"20","author":"Solomon","year":"2001","journal-title":"DNA Cell Biol"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2011.08.009_bib0275","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nn842","article-title":"Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model","volume":"5","author":"Dodart","year":"2002","journal-title":"Nat Neurosci"},{"issue":"September (36)","key":"10.1016\/j.vaccine.2011.08.009_bib0280","doi-asserted-by":"crossref","first-page":"33012","DOI":"10.1074\/jbc.M203193200","article-title":"Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation","volume":"277","author":"Mohajeri","year":"2002","journal-title":"J Biol Chem"},{"issue":"May (4)","key":"10.1016\/j.vaccine.2011.08.009_bib0285","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0896-6273(03)00294-0","article-title":"Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease","volume":"38","author":"Hock","year":"2003","journal-title":"Neuron"},{"issue":"November (5597)","key":"10.1016\/j.vaccine.2011.08.009_bib0290","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1126\/science.1078259","article-title":"Cerebral hemorrhage after passive anti-Abeta immunotherapy","volume":"298","author":"Pfeifer","year":"2002","journal-title":"Science"},{"issue":"September (3)","key":"10.1016\/j.vaccine.2011.08.009_bib0295","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00401-010-0719-5","article-title":"Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis","volume":"120","author":"Boche","year":"2010","journal-title":"Acta Neuropathol"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2011.08.009_bib0300","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","article-title":"Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report","volume":"9","author":"Nicoll","year":"2003","journal-title":"Nat Med"},{"issue":"July\u2013August (4)","key":"10.1016\/j.vaccine.2011.08.009_bib0305","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5414\/NPP29209","article-title":"Cerebral amyloid angiopathy and microhemorrhages after amyloid beta vaccination: case report and brief review","volume":"29","author":"Uro-Coste","year":"2010","journal-title":"Clin Neuropathol"},{"issue":"May (12)","key":"10.1016\/j.vaccine.2011.08.009_bib0310","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1016\/j.febslet.2005.03.070","article-title":"Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis","volume":"579","author":"Lee","year":"2005","journal-title":"FEBS Lett"},{"issue":"July (2)","key":"10.1016\/j.vaccine.2011.08.009_bib0315","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neuint.2006.03.017","article-title":"Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice","volume":"49","author":"Morgan","year":"2006","journal-title":"Neurochem Int"},{"key":"10.1016\/j.vaccine.2011.08.009_bib0320","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1742-2094-7-57","article-title":"Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Abeta\/amyloid burden in a transgenic mouse model of Alzheimer's disease","volume":"7","author":"Minami","year":"2010","journal-title":"J Neuroinflamm"},{"issue":"July (1)","key":"10.1016\/j.vaccine.2011.08.009_bib0325","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/jnr.10286","article-title":"Reversal of amyloid beta toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid beta antibody","volume":"69","author":"Chauhan","year":"2002","journal-title":"J Neurosci Res"},{"issue":"October (1)","key":"10.1016\/j.vaccine.2011.08.009_bib0330","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/jnr.10721","article-title":"Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576","volume":"74","author":"Chauhan","year":"2003","journal-title":"J Neurosci Res"},{"issue":"December (5)","key":"10.1016\/j.vaccine.2011.08.009_bib0335","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/jnr.20298","article-title":"Effect of age on the duration and extent of amyloid plaque reduction and microglial activation after injection of anti-Abeta antibody into the third ventricle of TgCRND8 mice","volume":"78","author":"Chauhan","year":"2004","journal-title":"J Neurosci Res"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2011.08.009_bib0340","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/85525","article-title":"Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy","volume":"7","author":"Bacskai","year":"2001","journal-title":"Nat Med"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2011.08.009_bib0345","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/1389557023406575","article-title":"Towards Alzheimer's disease vaccination","volume":"2","author":"Solomon","year":"2002","journal-title":"Mini Rev Med Chem"},{"issue":"March (17\u201318)","key":"10.1016\/j.vaccine.2011.08.009_bib0350","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1016\/j.vaccine.2005.01.034","article-title":"Generation of anti-beta-amyloid antibodies via phage display technology towards Alzheimer's disease vaccination","volume":"23","author":"Solomon","year":"2005","journal-title":"Vaccine"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2011.08.009_bib0355","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3233\/JAD-2006-9S349","article-title":"Alzheimer's disease immunotherapy: from in vitro amyloid immunomodulation to in vivo vaccination","volume":"9","author":"Solomon","year":"2006","journal-title":"J Alzheimers Dis"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2011.08.009_bib0360","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neulet.2004.10.090","article-title":"Efficacy of anti-Abeta antibody isotypes used for intracerebroventricular immunization in TgCRND8","volume":"375","author":"Chauhan","year":"2005","journal-title":"Neurosci Lett"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2011.08.009_bib0365","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/jnr.21110","article-title":"Intracerebroventricular passive immunization with anti-oligoAbeta antibody in TgCRND8","volume":"85","author":"Chauhan","year":"2007","journal-title":"J Neurosci Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11012187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11012187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T12:12:13Z","timestamp":1592827933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11012187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":73,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0264410X11012187"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.08.009","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}